NCT05769010View on ClinicalTrials.gov

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

October 30, 2025

Study Completion Date

April 30, 2026

Conditions
Metastatic Breast Cancer
Interventions
DRUG

SHR-A1811

SHR-A1811: intravenous

DRUG

Pyrotinib

Pyrotinib: oral

DRUG

Bevacizumab

Bevacizumab: intravenous

Trial Locations (1)

Unknown

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV